stockrow
Friday 6 November 2026
Export TTOO’s income statement to Excel — free account
T2 Biosystems, Inc.
TTOO Healthcare Diagnostics & Research
T2 Biosystems, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $7.2 million, down 67.8% from fiscal 2022.
0.00
0.00
NaN
Follow TTOO
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 3 | 6 | 2 | 5 | 5 | 2 | 2 |
P/S ratio |
33.33 | 30.38 | 11.61 | 6.39 | 8.31 | 2.93 | 0.37 | 1.96 |
Altman Z-Score |
(2.50) | (8.63) | (7.59) | (25.47) | (7.04) | (11.48) | (26.06) | (28.92) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(5.61) | (23.28) | (20.12) | (65.50) | (17.19) | (26.84) | (60.34) | (70.64) |
P/Operating CF |
(13.20) | (12.80) | (12.58) | (5.26) | (17.22) | (8.34) | (0.79) | (1.50) |
Beneish M-Score |
— | — | — | — | — | (4.19) | (2.75) | — |
P/B ratio |
3.46 | 105.79 | 10.71 | 0.00 | 17.27 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
3.46 | 105.79 | 10.71 | 0.00 | 17.27 | 0.00 | 0.00 | 0.00 |
EV/Sales |
25.19 | 21.80 | 6.82 | 5.29 | 8.48 | 3.48 | 2.13 | 6.75 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(2.21) | (2.13) | (1.78) | (0.97) | (3.56) | (2.51) | (0.94) | (1.01) |
EV/FCF |
(1.98) | (2.03) | (1.76) | (0.96) | (3.49) | (2.48) | (0.93) | (1.00) |
Quick Ratio |
7.47 | 0.82 | 1.01 | 0.23 | 4.83 | 3.20 | 1.23 | 0.30 |
Current Ratio |
7.63 | 0.86 | 1.08 | 0.31 | 5.47 | 3.80 | 1.91 | 0.45 |
Net Debt/EBITDA |
0.68 | 0.79 | 1.18 | 0.19 | (0.08) | (0.39) | (0.73) | 0.32 |
Debt/Assets |
44.99% | 3.17% | 0.77% | 6.58% | 57.20% | 78.94% | 144.64% | 0.00% |
Debt/Equity |
1.02 | 1.30 | 0.04 | (0.06) | 5.18 | (3.70) | (1.25) | 0.00 |
Asset Turnover |
0.05 | 0.06 | 0.18 | 0.18 | 0.34 | 0.40 | 0.47 | 0.21 |
Operating CF/Net income |
0.85 | 0.76 | 0.78 | 0.77 | 0.92 | 0.79 | 0.81 | 0.96 |
Capex/Depreciation |
(2.41) | (0.84) | (0.24) | (0.21) | (0.25) | (0.17) | (0.32) | (0.22) |
Interest Coverage |
(12.42) | (6.05) | (6.75) | (7.08) | (7.49) | (5.66) | (9.07) | (9.30) |
| (127.04%) | (306.94%) | (803.85%) | 521.76% | 370.25% | 2,357.72% | 237.20% | 147.96% | |
| (62.14%) | (86.45%) | (85.85%) | (127.17%) | (87.01%) | (70.54%) | (131.41%) | (144.89%) | |
ROIC |
(517.39%) | 0.00% | 0.00% | 0.00% | (219.57%) | (1,015.05%) | 0.00% | 0.00% |
Return on Tangible Assets |
(69.25%) | (2,447.20%) | (439.99%) | 164.67% | (98.41%) | (131.73%) | (452.87%) | 170.88% |
Average Days of Receivables |
29.25 | 36.53 | 62.08 | 123.71 | 102.66 | 66.79 | 35.40 | 72.06 |
Research and Development Expense of Revenue |
588.46% | 508.64% | 137.99% | 195.87% | 88.87% | 77.70% | 115.29% | 196.76% |
Selling, General and Administrative Expense of Revenue |
590.12% | 487.72% | 244.73% | 327.58% | 121.86% | 101.67% | 137.30% | 345.20% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
118.82% | 102.66% | 94.26% | 65.48% | 21.58% | 25.27% | 29.11% | 60.49% |
Graham Net Nets |
0.19 | (0.06) | 0.03 | (0.82) | (0.11) | (0.35) | (6.69) | (2.67) |
Graham Number |
0.00 | 0.00 | 0.00 | 23,377.53 | 0.00 | 3,700.57 | 5,002.43 | 187.53 |
Earnings Yield |
(40.34%) | (43.77%) | (42.52%) | (111.11%) | (37.10%) | (58.12%) | (893.99%) | (2,689.67%) |
Free Cash Flow Yield |
(38.19%) | (35.41%) | (33.41%) | (86.64%) | (29.21%) | (47.92%) | (624.61%) | (342.26%) |
Revenue per Share |
784.62 | 729.06 | 1,296.30 | 915.93 | 746.09 | 882.33 | 437.35 | 2.76 |
Operating CF per Share |
(8,931.15) | (7,455.94) | (4,955.31) | (4,984.73) | (1,778.40) | (1,222.45) | (992.73) | (18.44) |
Capex per Share |
(1,055.19) | (386.87) | (73.21) | (83.63) | (32.92) | (14.47) | (6.65) | (0.07) |
Free Cash Flow per Share |
(9,986.35) | (7,842.81) | (5,028.52) | (5,068.35) | (1,811.32) | (1,236.92) | (999.37) | (18.52) |
Cash per Share |
14,132.31 | 6,531.09 | 6,272.22 | 1,212.42 | 1,736.17 | 1,013.87 | 202.53 | 6.01 |
Shareholders Equity per Share |
7,565.00 | 209.38 | 1,405.80 | (3,736.81) | 359.09 | (405.75) | (777.55) | (10.74) |
Interest Debt per Share |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7,565.00 | 209.38 | 1,405.80 | (3,736.81) | 359.09 | (405.75) | (777.55) | (10.74) |
Free Cash Flow |
(51.93) | (50.19) | (40.73) | (46.12) | (44.01) | (39.33) | (50.97) | (48.33) |
Working Capital |
65.55 | (7.46) | 4.31 | (41.68) | 43.78 | 32.71 | 9.23 | (30.96) |
Capital Expenditures |
(5.49) | (2.48) | (0.59) | (0.76) | (0.80) | (0.46) | (0.34) | (0.19) |
Net Current Asset Value |
25.21 | (9.20) | 3.69 | (43.60) | (16.77) | (29.05) | (54.62) | (37.64) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
1.34 | 0.53 | 0.06 | 0.09 | 0.04 | 0.02 | 0.02 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.17 | 0.29 | 0.33 | 0.62 | 0.86 | 0.58 | 0.23 | 0.52 |
Cash ROIC |
(33.91%) | (111.85%) | (64.98%) | 218.60% | (45.78%) | (58.60%) | (250.77%) | 391.41% |
Accounts Receivable Turnover |
11.72 | 11.75 | 9.32 | 3.62 | 4.58 | 5.48 | 6.11 | 4.02 |
Accounts Payable Turnover |
6.28 | 14.94 | 22.13 | 7.46 | 7.32 | 8.47 | 10.18 | 10.88 |
Inventory Turnover |
9.25 | 11.20 | 7.66 | 5.34 | 5.88 | 5.49 | 5.13 | 3.38 |
Average Days of Payables |
51.10 | 19.66 | 17.63 | 81.72 | 35.30 | 49.93 | 22.52 | 36.28 |
Days of Inventory on Hand |
42.65 | 40.78 | 63.43 | 78.37 | 62.37 | 68.92 | 74.44 | 114.49 |
Average Receivables |
0.35 | 0.40 | 1.13 | 2.31 | 3.96 | 5.12 | 3.65 | 1.79 |
Average Payables |
1.10 | 0.81 | 0.70 | 2.25 | 2.91 | 2.45 | 2.06 | 1.41 |
Average Inventory |
0.74 | 1.07 | 2.01 | 3.14 | 3.62 | 3.77 | 4.10 | 4.55 |
Average Assets |
88.20 | 72.21 | 59.59 | 46.40 | 53.78 | 69.81 | 47.43 | 34.56 |
Average Common Equity |
43.14 | 20.34 | 6.36 | (11.31) | (12.64) | (2.09) | (26.28) | (33.85) |
Columns are period end dates · fundamentals updated 26 Oct 2026